The coronavirus vaccine being developed by Oxford University has passed the second phase of trials, showing good results in the elderly – over 60 and 70 years old. It was reported on Thursday, November 19, by the BBC Russian Service.
Currently, the third phase of testing has started, with volunteers from around the world participating in it. Primary results are expected to appear before the end of the year.
The UK has pre-contracts for tens of millions of doses of six candidate vaccines currently in clinical trials. The country's greatest hopes are pinned on the Oxford University vaccine, developed jointly with the British-Swedish pharmaceutical company AstraZeneca.
The third phase of testing is taking place in the UK, Brazil, India, South Africa, Japan and should soon resume in the United States. Earlier in October, one of the participants in the vaccine trials died “as a result of complications from COVID-19,” but they decided to continue testing the drug.